The decision follows a September meeting of the agency's Gastrointestinal Drugs Advisory Committee, which agreed that the farnesoid X receptor (FXR) agonist did not have a favorable benefit-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback